Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Kendall Antifungal is an over-the-counter topical antifungal cream containing 2% miconazole nitrate, an imidazole-class small-molecule azole antifungal developed originally by Janssen that is widely used for superficial dermatophyte and yeast infections. It acts by inhibiting fungal CYP450 14α-lanosterol demethylase, disrupting ergosterol synthesis and membrane integrity, which leads to leakage of intracellular contents and fungal cell death or growth inhibition. Clinically, the product is indicated for treatment of tinea pedis (athlete’s foot), tinea cruris (jock itch), and tinea corporis (ringworm), providing symptomatic relief of itching, scaling, cracking, burning, and associated irritation when applied topically to affected skin.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Kendall Antifungal.